bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma

Modern Pathology

Volumn 9, Issue 4, 1996, Pages 430-438

  Henderson, Gregory Stephen ^a,b   Brown, Karen A ^a   Perkins, Sherrie L ^a   Abbott, Thomas M ^a   Clayton, Frederic ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Atypical hyperplasia; Bcl 2 protein; Endometrial carcinoma; Immunohistochemistry; Oncogene

Indexed keywords

PROTEIN BCL 2;

ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA; DOWN-REGULATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, BCL-2; HUMANS; METAPLASIA; UTERINE CERVICAL DISEASES; UTERINE CERVICAL DYSPLASIA;

EID: 0029882098     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
2. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879, 1992
3. Reed JC: bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
4. Korsmeyer SJ, Shutter JR, Veis DJ, Oltvai ZN: bcl-2/Bax: A rheostat that regulates an antioxidant pathway and cell death. Semin Cancer Biol 4:327, 1993
5. Vaux DL: Toward an understanding of the molecular mechanisms of physiological cell death. Proc Nat Acad Sci U S A 90:786, 1993
6. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961, 1991
7. Lu Q-L, Poulson R, Wong L, Hanby A: bcl-2 expression in adult and embryonic nonhaematopoietic tissues. J Pathol 169:431, 1993
8. Gompel A, Sabourin JC, Martin A, et al.: bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144:1195, 1994
9. Otsuki Y, Misaki O, Sugimoto O, et al.: Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 344:28, 1994
10. Sabourin JC, Martin A, Baruch J, et al.: bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59:1, 1994
11. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours, and in situ cancer. Br J Cancer 69:135, 1994
12. Tsujimoto Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440, 1985
13. Bakhshi A, Jensen JP, Goldman P, et al.: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
14. Cleary ML, Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439, 1985
15. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybird bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19, 1986
16. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 83:5214, 1986
17. McDonnell TJ, Deane N, Platt F: bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 57:79, 1989
18. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ: Expression of bcl-2 and bcl-2 fusion transcripts in normal and neoplastic cells. J Clin Invest 80:1512, 1987
19. McDonnell TJ, Nunez G, Platt F: Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M- and D-expressing B-cell population. Mol Cell Biol 10:1901, 1990
20. Nunez G, London L, Hockenberry D: Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602, 1990
21. Chen-Leavy Z, Nourse J, Cleary M: The bcl-2 candidate proto-oncogene product is a 24-kDa integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9:701, 1989
22. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254, 1991
23. Pezzella F, Tse AG, Cordell JL, et al.: Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225, 1990
24. Bhargava V, Kell DL, van de Rijn M, Warnke RA: bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535, 1994
25. Nathan B, Gusterson B, Jadayel D, et al. for the International (Ludwig) Breast Cancer Study Group: Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5:409, 1994
26. Silverberg SG: Clinical-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous estrogens. Cancer 45:3018, 1980
27. Kelsey JL: A case control study of cancer ot the endometrium. Am J Epidemiol 116:333, 1982
28. Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167, 1975
29. Kurman RJ, Norris HJ: Endometrial hyperplasia and related cellular changes. In Blaustein's Pathology of the Female Genital Tract, edited by Kurman RJ, p 412. New York, Springer-Verlag, 1994
30. Swanson PE: Microwave antigen retrieval in citrate buffer. Lab Med 25:520, 1994
31. Brown KA, Henderson GS, Fiack JF: Response to "Microwave antigen retrieval in citrate buffer." Lab Med 25:800, 1994
32. Segal GH, Jorgensen T, Scott M, Braylan RC: Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. Follicular lymphomas. Hum Pathol 25: 1276, 1994
33. Spritz RA, Jagadeeswaran P, Choudary PV, et al.: Base substitution in an intervening sequence of a beta-thalassemia human globin gene. Proc Natl Acad Sci U S A 78:2455, 1981
34. Crescenzi M, Seto M, Herzig GP, et al.: Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci U S A 85:4869, 1988
35. Said JW, Sasson AF, Shintaku IP, et al.: Polymerase chain reaction for bcl-2 in diagnostic lymph node biopsies. Mod Pathol 3:659, 1990
36. Chen YT, Whitney KD, Chen Y: Clonality analysis of B-cell lymphoma in fresh-frozen and paraffin-embedded tissues: The effects of variable polymerase chain reaction parameters. Mod Pathol 7:429, 1994
37. Ambros RA, Kurman RJ: Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 69:1424, 1992
38. Gusberg SB, Kaplan AL: Precursors of corpus cancer. IV. Adenomatous hyperplasia as stage 0 carcinoma of the endometrium. Am J Obstet Gynecol 87:662, 1963
39. Kurman RJ, Norris HJ: Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 49:2547, 1982
40. Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56:403, 1985
41. Tavassoli F, Kraus FT: Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 70: 770, 1978
42. Gauwesky CE, Hoxie J, Vomell PC, Croce CM: Pre-B-cell leukemia with a t(8;14) and a t(14;18) translocation is preceded by follicular lymphoma. Oncogene 2:431, 1988
43. Shah NK, Currie JL, Rosenshein N, et al.: Cytogenetic and FISH analysis of endometrial carcinoma. Cancer Genet Cytogenet 73:142, 1994
44. Gima T, Kato H, Honda T, et al.: DCC gene alteration in human endometrial carcinomas. Int J Cancer 57:480, 1994
45. Ronnett BM, Burks RT, Cho KR, Hedrick L: DCC expression in normal and neoplastic endometrial tissue. Mod Pathol 8:96A, 1995.
46. Tron VA, Krajewski S, Klein-Parker H, et al.: Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146:643, 1995
47. Gordon J, Reagan JW, Finkle WD, Ziel HK: Estrogens and endometrial carcinoma. An independent pathology review supporting original risk estimate. N Engl J Med 297:570, 1977
48. Kraus FT: High-risk and premalignant lesions of the endometrium. Am J Surg Pathol 9(Suppl):31, 1985
49. Norris HJ, Becker RL, Mikel UV: A comparative morphometric and cytomorphometric study of endometrial hyperplasia, atypical hyperplasia, and endometrial carcinoma. Hum Pathol 20:219, 1989